Skip to main content
. 2017 May 7;8(29):47507–47517. doi: 10.18632/oncotarget.17670

Table 3. Different NA therapies in HCC and control groups.

HCC< (n = 57) Non-HCC (n = 57)
Entecavir 38 (66.7%) 50 (87.7%)
Lamivudine 9 (15.8%) 3 (5.3%)
Telbivudine 1 (1.8%) 1 (1.8%)
Adefovir 6 (10.5%) 2 (3.5%)
Tenofovir 3 (5.3%) 1 (1.8%)

NA, nucleos(t)ide analogue; HCC, hepatocellular carcinoma.